All In MedTech

FDA Clearance Tracker · P190032-S009

FoundationOne Liquid CDx (F1 Liquid CDx)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 8, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 8, 2023

Approved

Time to decision

180 days

Received Sep 9, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P190032-S009
Device name
FoundationOne Liquid CDx (F1 Liquid CDx)
Applicant location
Boston, MA
Received
Sep 9, 2022
Decided
Mar 8, 2023
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P190032

Device type

Device class
Class III

Every decision under product code PQP

FDA's approval statement

As written in FDA's record.

Approval for Waiver of Condition of Approval (CoA) for Contrived Sample Functional Characterization (CSFC) study for F1 Liquid CDx.

Source documents

Other decisions for Foundation Medicine, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.